This triple-agonist mechanism makes it a subject of intense interest in metabolic research, exploring pathways related to energy expenditure, glucose control, and appetite regulation
In addition, a significant improvement in the first and second phase of insulin secretion was observed with tirzepatide treatment, as well as an improvement in beta cell function, estimated with beta-cell glucose sensitivity
Burg D, Riepsaame J, Pont C, Mulder G, van de Water B
GLP-1s lower our desire for food productsrather than have us rely on willpower or other avoidance strategies
The FDA said the shortage of semaglutide injection products such as Novo Nordisk's Ozempic and Wegovy has been resolved
Persistent or severe hypoglycemic episodes despite proper meal timing